Search alternatives:
significant greater » significantly greater (Expand Search), significant gender (Expand Search), significant rates (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
significant greater » significantly greater (Expand Search), significant gender (Expand Search), significant rates (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
-
61
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
62
-
63
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
64
-
65
-
66
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
67
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80